Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
卡瑞利珠单抗联合阿帕替尼治疗可切除肝细胞癌围手术期疗效及安全性:一项单臂、开放标签、II期临床试验
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2022-004656
Xia, Yongxiang; Tang, Weiwei; Qian, Xiaofeng; Li, Xiangcheng; Cheng, Feng; Wang, Ke; Zhang, Feng; Zhang, Chuanyong; Li, Donghua; Song, Jinhua; Zhang, Hui; Zhao, Jie; Yao, Aihua; Wu, Xiaofeng; Wu, Chen; Ji, Guwei; Liu, Xisheng; Zhu, Feipeng; Qin, Lang; Xiao, Xuan; Deng, Zhenhua; Kong, Xiangyi; Li, Si; Yu, Yangyang; Xi, Wenjing; Deng, Wanglong; Qi, Chuang; Liu, Hanyuan; Pu, Liyong; Wang, Ping; Wang, Xuehao